Castration-sensitive Prostate Cancer (CSPC) – Epidemiology Forecast – 2034
Description
Key Highlights
Prostate cancer patients often undergo repeated screenings, and the number of screenings is estimated to increase by 2–3% annually due to the rising prevalence of the disease.
Recent global trends indicate a rising incidence of prostate cancer in many countries, likely driven by aging populations and improved access to diagnostic tools.
The five-year prevalent cases of CSPC in the US comprised about more than 300,000 cases in 2024 and are projected to increase during the forecast period (2025–2034), aging populations and increased awareness are expected to expand the CSPC patient pool.
Metastatic prostate cancer is increasingly viewed as a chronic condition, with improved survival rates due to new treatments. The 5-year prevalence better reflects the growing population of long-term survivors and their ongoing treatment needs, which is crucial for pharmaceutical market assessment and strategy.
Biochemical recurrence develops in almost one-third of men with prostate cancer after treatment with local therapy.
Improved screening and awareness are leading to earlier diagnosis, keeping more patients in the CSPC stage for longer periods before progression.
DelveInsight’s “Castration-sensitive Prostate Cancer (CSPC) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CSPC, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Castration-sensitive Prostate Cancer (CSPC) Understanding
Castration-sensitive Prostate Cancer (CSPC) Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. Prostate cancer is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. Metastatic castration-sensitive prostate cancer (mCSPC), also referred to as metastatic hormone-sensitive prostate cancer (mHSPC), is an advanced form of prostate cancer (biochemical progression or proven metastases) defined by disease that has spread from the prostate into other regions of the body and that remains responsive to hormone therapy. Depending on the detection of metastases on imaging, the stage is referred to as M0 CSPC or M1 CSPC. It is not easy to distinguish stage M0 CSPC from a local recurrence after curative therapy. Histology and PSA are helpful in this context.
Castration-sensitive Prostate Cancer (CSPC) Diagnosis
Advanced cancer may be found before, at the same time, or later than the main tumor. Most diagnosed with advanced prostate cancer have had biopsy and treatment in the past. When a new tumor is found in someone who has been treated for cancer in the past, usually cancer has spread. The following tests are used to diagnose and track prostate cancer. PSA is a protein found in prostate cells that helps to keep semen liquified. Most cases of prostate cancer develop in these cells, so an elevated PSA count may be a sign of prostate cancer. However, PSA results are more of an indicator than a firm diagnostic tool—there’s not a certain PSA score that means a man has prostate cancer. The digital rectal exam is a physical exam to feel for changes in the prostate. This test may also be used to screen for and stage cancer or track how well treatment is going.
Further details related to country-based variations in diagnosis are provided in the report…
Castration-sensitive Prostate Cancer (CSPC) Epidemiology
As the market is derived using a patient-based model, the Castration-sensitive Prostate Cancer (CSPC) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Prostate cancer, Five-year Prevalent cases of Prostate cancer, Age-specific cases of Prostate cancer, Total cases of Prostate cancer by clinical stages, Five-year Prevalent cases of CSPC, Total Prevalent cases of mCSPC and nmCSPC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The five-year prevalent cases of prostate cancer in the US was approximately 1.1 million in 2024.
As per the analysis, in the United States, approximately 40% of prostate cancer cases are diagnosed in individuals aged 65-74 years, representing the most common age group for this disease.
As per the estimates, in the US, majority of the cases were found to be localized/locally advanced cases (Stage I-III), comprising approximately 56% of total cases, while nearly 33% belonged to biochemical recurrence/ progressive cases, and ~11% belonged to metastatic cases.
In Japan, mCSPC cases made up approximately 21% of the total prevalent cases of CSPC.
Castration-sensitive Prostate Cancer (CSPC) Report Insights
Castration-sensitive Prostate Cancer (CSPC) Report Insights
Patient population
Country-wise epidemiology distribution
Castration-sensitive Prostate Cancer (CSPC) report key strengths
Ten-year forecast
7MM coverage
CSPC epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of castration-sensitive prostate cancer? What will be the growth opportunities across the 7MM concerning the patient population with castration-sensitive prostate cancer?
What is the historical and forecasted castration-sensitive prostate cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Prostate cancer patients often undergo repeated screenings, and the number of screenings is estimated to increase by 2–3% annually due to the rising prevalence of the disease.
Recent global trends indicate a rising incidence of prostate cancer in many countries, likely driven by aging populations and improved access to diagnostic tools.
The five-year prevalent cases of CSPC in the US comprised about more than 300,000 cases in 2024 and are projected to increase during the forecast period (2025–2034), aging populations and increased awareness are expected to expand the CSPC patient pool.
Metastatic prostate cancer is increasingly viewed as a chronic condition, with improved survival rates due to new treatments. The 5-year prevalence better reflects the growing population of long-term survivors and their ongoing treatment needs, which is crucial for pharmaceutical market assessment and strategy.
Biochemical recurrence develops in almost one-third of men with prostate cancer after treatment with local therapy.
Improved screening and awareness are leading to earlier diagnosis, keeping more patients in the CSPC stage for longer periods before progression.
DelveInsight’s “Castration-sensitive Prostate Cancer (CSPC) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CSPC, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Castration-sensitive Prostate Cancer (CSPC) Understanding
Castration-sensitive Prostate Cancer (CSPC) Overview
Prostate cancer is a type of malignancy that occurs in the prostate gland. Prostate cancer is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm. Metastatic castration-sensitive prostate cancer (mCSPC), also referred to as metastatic hormone-sensitive prostate cancer (mHSPC), is an advanced form of prostate cancer (biochemical progression or proven metastases) defined by disease that has spread from the prostate into other regions of the body and that remains responsive to hormone therapy. Depending on the detection of metastases on imaging, the stage is referred to as M0 CSPC or M1 CSPC. It is not easy to distinguish stage M0 CSPC from a local recurrence after curative therapy. Histology and PSA are helpful in this context.
Castration-sensitive Prostate Cancer (CSPC) Diagnosis
Advanced cancer may be found before, at the same time, or later than the main tumor. Most diagnosed with advanced prostate cancer have had biopsy and treatment in the past. When a new tumor is found in someone who has been treated for cancer in the past, usually cancer has spread. The following tests are used to diagnose and track prostate cancer. PSA is a protein found in prostate cells that helps to keep semen liquified. Most cases of prostate cancer develop in these cells, so an elevated PSA count may be a sign of prostate cancer. However, PSA results are more of an indicator than a firm diagnostic tool—there’s not a certain PSA score that means a man has prostate cancer. The digital rectal exam is a physical exam to feel for changes in the prostate. This test may also be used to screen for and stage cancer or track how well treatment is going.
Further details related to country-based variations in diagnosis are provided in the report…
Castration-sensitive Prostate Cancer (CSPC) Epidemiology
As the market is derived using a patient-based model, the Castration-sensitive Prostate Cancer (CSPC) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Prostate cancer, Five-year Prevalent cases of Prostate cancer, Age-specific cases of Prostate cancer, Total cases of Prostate cancer by clinical stages, Five-year Prevalent cases of CSPC, Total Prevalent cases of mCSPC and nmCSPC in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.
The five-year prevalent cases of prostate cancer in the US was approximately 1.1 million in 2024.
As per the analysis, in the United States, approximately 40% of prostate cancer cases are diagnosed in individuals aged 65-74 years, representing the most common age group for this disease.
As per the estimates, in the US, majority of the cases were found to be localized/locally advanced cases (Stage I-III), comprising approximately 56% of total cases, while nearly 33% belonged to biochemical recurrence/ progressive cases, and ~11% belonged to metastatic cases.
In Japan, mCSPC cases made up approximately 21% of the total prevalent cases of CSPC.
Castration-sensitive Prostate Cancer (CSPC) Report Insights
Castration-sensitive Prostate Cancer (CSPC) Report Insights
Patient population
Country-wise epidemiology distribution
Castration-sensitive Prostate Cancer (CSPC) report key strengths
Ten-year forecast
7MM coverage
CSPC epidemiology segmentation
FAQs
What are the disease risks, burdens, and unmet needs of castration-sensitive prostate cancer? What will be the growth opportunities across the 7MM concerning the patient population with castration-sensitive prostate cancer?
What is the historical and forecasted castration-sensitive prostate cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
142 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary of CSPC
- 4. Epidemiology Forecast Methodology
- 5. Disease Background and Overview
- 5.1. Signs and Symptoms of Prostate Cancer
- 5.2. Grading and Staging
- 5.3. Risk Factors and Causes of Prostate Cancer
- 5.4. Biochemical Recurrence
- 5.5. Diagnosis
- 6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Assumptions and Rationale
- 6.3. Total Prevalent Cases of Prostate Cancer in the 7MM
- 6.4. Five-year Prevalent Cases of Prostate Cancer in the 7MM
- 6.5. Total Prevalent Cases of CSPC in the 7MM
- 6.5.1. Total Prevalent Cases of nmCSPC in the 7MM
- 6.5.2. Total Prevalent Cases of mCSPC in the 7MM
- 6.6. The United States
- 6.6.1. Five-year Prevalent Cases of Prostate Cancer in the US
- 6.6.2. Age-specific Cases of Prostate Cancer in the US
- 6.6.3. Total Prevalent Cases of Prostate Cancer by Clinical Stages in the US
- 6.6.4. Total Prevalent Cases of CSPC in the US
- 6.6.4.1. Total Prevalent Cases of nmCSPC in the US
- 6.6.4.2. Total Prevalent Cases of mCSPC in the US
- 6.7. EU4 and the UK
- 6.7.1. Five-year Prevalent Cases of Prostate Cancer in EU4 and the UK
- 6.7.2. Age-specific Cases of Prostate Cancer in EU4 and the UK
- 6.7.3. Total Prevalent Cases of Prostate Cancer by Clinical Stages in EU4 and the UK
- 6.7.4. Total Prevalent Cases of CSPC in EU4 and the UK
- 6.7.4.1. Total Prevalent Cases of nmCSPC in EU4 and the UK
- 6.7.4.2. Total Prevalent Cases of mCSPC in EU4 and the UK
- 6.8. Japan
- 6.8.1. Five-year Prevalent Cases of Prostate Cancer in Japan
- 6.8.2. Age-specific Cases of Prostate Cancer in Japan
- 6.8.3. Total Prevalent Cases of Prostate Cancer by Clinical Stages in Japan
- 6.8.4. Total Prevalent Cases of CSPC in Japan
- 6.8.4.1. Total Prevalent Cases of nmCSPC in Japan
- 6.8.4.2. Total Prevalent Cases of mCSPC in Japan
- 7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
- 8. DelveInsight Capabilities
- 9. Disclaimer
- 10. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
